Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Titans Of Pharma – A Snapshot Of The Industry's Top Leaders, An Infographic

Executive Summary

In 2016, the 15 top pharma companies paid their CEOs $276m in total* while those same firms reported a total net income of $96.5bn**. Altogether these companies had a market capitalization of $2,238bn on June 30, 2017**. In this infographic Scrip gives a snapshot of these companies' leaders and the businesses they oversee.

You may also be interested in...



Titans of Pharma 2018: An Infographic Snapshot Of The Industry's Top Leaders

In 2017, the top 15 pharma companies paid their CEOs a total of $251m in salary and other benefits, while reporting net income of $56.5bn. But while income was down 41% on 2016, compensation declined by a more modest 9%. In this infographic, Scrip provides a snapshot of these companies' leaders and the businesses they oversee.

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer

Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.

Topics

UsernamePublicRestriction

Register

MT142249

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel